FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

					or	Sectio	n 30(h) of	thè Í	nvestmen	t Cor	npany Act o	f 1940								
1. Name and Address of Reporting Person* MAIER PAUL V				2. Issuer Name and Ticker or Trading Symbol Eton Pharmaceuticals, Inc. [ETON]								5. (C	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
													X	Director			10% Ow	ner		
(Last)	(Firs	,	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 05/03/2021									Officer (give title Other (spec below) below)						
21925 W FIELD PKWY, SUITE 235																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) DEER PAI	RK IL	6	0010-727	Ω										X	Form fil	ed by One	Repoi	rting Person		
,————	XIX IL		0010-727											Form filed by More than One Reporting Person					ing	
(City)	(Stat	te) (Z	ip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
4 7711 - 150			- 1101				A. Deeme		3.		1			,	1		c 0		. Nature of	
1. Title of Security (Instr. 3) 2. Transc Date (Month/L			Day/Year) if		ZA. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		es Acquired (A) Of (D) (Instr. 3, 4		d	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price			eported ansaction(s) nstr. 3 and 4)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivat Securit		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	/e es ally ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amour or Number of Shares	er						
Stock Option(Right	\$8.61	05/03/2021			A		19,655		(1)		05/03/2031	Common	19,65	5	\$0.00	59,555	5	D		

Explanation of Responses:

to buy)

1. The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.

/s/ W. Wilson Troutman 05/05/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.